Clinical Insights for Hair Restoration: A Case Study on UC-MSCs Derived Secretome Therapy in Alopecia

The case study explores the use of UC-MSCs derived secretome therapy for treating alopecia in a 38-year-old male with androgenetic alopecia, Norwood-Hamilton type III. The treatment involved two intradermal administrations of 2 cc of the secretome, one month apart. Results showed a significant increase in hair density from 50 to 75 hairs per cm and a reduction in follicular miniaturization, indicating healthier hair growth and stabilization of hair loss. No adverse effects were reported, suggesting the treatment's safety and tolerability. The study concludes that UC-MSCs derived secretome therapy may be a promising treatment for alopecia, but further research with a larger patient population is needed to confirm its efficacy and determine optimal protocols.